Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial.

2018年にCIDで報告されたRCT。

話題になりました。地味ですが、臨床インパクトあるRCT。

感想

症状安定なら、ショートでいいかもね。

Abstract

BACKGROUND:

Gram-negative bacteremia is a major cause of morbidity and mortality in hospitalized patients. Data to guide the duration of antibiotic therapy are limited.

METHODS:

Randomized, multicenter, open-label, non-inferiority trial. Inpatients with Gram-negative bacteremia, afebrile and hemodynamically stable for at least 48 hours, were randomized to receive 7 (intervention) or 14 days (control) of covering antibiotic therapy. Patients with uncontrolled focus of infection were excluded. The primary outcome at 90 days was a composite of all-cause mortality; relapse, suppurative or distant complications; and re-admission or extended hospitalization (>14 days). The non-inferiority margin was set at 10%.

RESULTS:

We included 604 patients (306 intervention, 298 control) between January 2013 and August 2017 in three centers in Israel and Italy. The source of the infection was urinary in 411/604 (68%); causative pathogens were mainly Enterobacteriaceae (543/604, 90%). A 7-day difference in the median duration of covering antibiotics was achieved. The primary outcome occurred in 140/306 (45.8%) patients in the 7 days group versus 144/298 (48.3%) in the 14 days group (risk difference [RD] -2.6%, 95% confidence interval [CI] -10.5% to 5.3%). No significant differences were observed in all other outcomes and adverse events, except for a shorter time to return to baseline functional status in the short therapy arm.

CONCLUSIONS:

In patients hospitalized with Gram-negative bacteremia achieving clinical stability before day 7, an antibiotic course of 7 days was non-inferior to 14 days. Reducing antibiotic treatment for uncomplicated Gram-negative bacteremia to 7 days is an important antibiotic stewardship intervention. (ClinicalTrials.gov number, NCT01737320).

引用　

1. Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in
hospitalized patients. Clin Infect Dis 2011; 52: 1232-40.
2. Corey GR, Stryjewski ME, Everts RJ. Short-course therapy for bloodstream infections in immunocompetent adults. Int J Antimicrob Agents 2009; 34: S47-51.
3. Eliakim-Raz N, Yahav D, Paul M, Leibovici L. Duration of antibiotic treatment for acute
pyelonephritis and septic urinary tract infection-- 7 days or less versus longer treatment:
systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2013; 68: 2183-91.
4. Royer S, DeMerle KM, Dickson RP, Prescott HC. Shorter Versus Longer Courses of
Antibiotics for Infection in Hospitalized Patients: A Systematic Review and Meta-Analysis. J Hosp Med 2018; 13: 336-342
5. Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy
for intraabdominal infection. N Engl J Med 2015; 372: 1996-2005.
6. Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a
systematic review and meta-analysis. Crit Care 2011; 15: R267.
7. Daneman N, Rishu AH, Pinto R, et al. 7 versus 14 days of antibiotic treatment for
critically ill patients with bloodstream infection: a pilot randomized clinical trial. Trials 2018; 19: 111.
8. Karakonstantis S, Kalemaki D. Blood culture useful only in selected patients with urinary tract infections - a literature review. Infect Dis (Lond) 2018; 50: 584-592.
9. Mandell GB, J. Dolin, R. Mandell, Douglas, And Bennett's Principles and Practice of
Infectious Diseases. Philadelphia, PA Elsevier/Saunders; 2015.

10. Daneman N, Rishu AH, Xiong W, et al. Duration of Antimicrobial Treatment for
Bacteremia in Canadian Critically Ill Patients. Crit Care Med 2016; 44: 256-64.
11. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and
management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.
12. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry. Available from:
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070981.pdf
13. Chotiprasitsakul D, Han JH, Cosgrove SE, et al. Comparing the Outcomes of Adults
With Enterobacteriaceae Bacteremia Receiving Short-Course Versus Prolonged-Course
Antibiotic Therapy in a Multicenter, Propensity Score-Matched Cohort. Clin Infect Dis 2018; 66:172-7.
14. Park SH, Milstone AM, Diener-West M, Nussenblatt V, Cosgrove SE, Tamma PD. Short versus prolonged courses of antibiotic therapy for children with uncomplicated Gram-negative bacteraemia. J Antimicrob Chemother 2014; 69: 779-85.
15. Giannella M, Pascale R, Toschi A, et al. Treatment duration for Escherichia coli
bloodstream infection and outcomes: retrospective single-centre study. Clin Microbiol Infect 2018. [Epub ahead of print]
16. Nelson AN, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. Optimal
duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections.Infection 2017; 45: 613-20.

17. Al-Hasan MN, Nelson AN, Justo JA, Albrecht H, Kohn J, Brandon Bookstaver P. Reply to comments: duration of antimicrobial therapy for Gram-negative bacteremia secondary to urinary source of infection. Infection 2018; 46: 283-84.
18. Daneman N, Rishu AH, Xiong W et al. Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): study protocol for a pilot randomized controlled trial. Trials. 2015; 16: 173.
19. Leibovici L. Long-term consequences of severe infections. Clin Microbiol Infect 2013; 19 : 510-2.
20. Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). Clin Infect Dis. 2015; 61 :800-6.

日本語版 サンフォード感染症治療ガイド2018(第48版)